<DOC>
	<DOCNO>NCT02260661</DOCNO>
	<brief_summary>First time patient study AZD8835 . The study four part . Part A AZD8835 administer single agent multiple ascend dose escalation phase investigate dose level monotherapy . Part B follow multiple ascend dose phase , additional patient tumor document PIK3CA gene mutation enrol single dose expansion phase . Part C second dose escalation phase post-menopausal patient estrogen receptor positive ( ER+ ) , HER2 negative breast cancer receive AZD8835 combination fulvestrant . Part D follow combination dose escalation phase study , additional postmenopausal patient ER+/HER2 negative breast cancer document PIK3CA gene mutation enrol AZD8835 fulvestrant combination dose-expansion phase maximum tolerate dose recommended phase II dose .</brief_summary>
	<brief_title>Phase I , Dose Study Look Safety Pharmacokinetics AZD8835 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description>AZD8835 novel small molecule inhibits cancer progression block PI3 kinase pathway component p110α p110δ . In first-time-in-patient study , AZD8835 initially administer single agent patient advance solid malignancy . Patients treat start dose 20 mg twice daily ( BID ) , administer weekly Days 1 4 escalated reach maximum-tolerated dose ( MTD ) patient define dose-limiting toxicity ( DLTs ) . A BID intermittent dose schedule administer weekly Days 1 4 oral formulation AZD8835 use , deem optimal effective non-clinical study , primarily determine safety tolerability AZD8835 . The pharmacokinetics ( PK ) AZD8835 potential biological activity also investigate . In Part A study , AZD8835 administer single agent multiple ascend dose escalation phase investigate appropriate monotherapy dose level clinical use . Additional dosing schedule may study , include dose Days 1 2 week , rather Days 1 4 . Backfilled pharmacodynamic ( PDc ) cohort select patient tumour document mutation phosphatidylinositol-4,5- bisphosphate 3-kinase , catalytic subunit alpha ( PIK3CA ) gene allow preliminary assessment biological effect AZD8835 patient . Following single-agent dose-escalation phase study , additional patient tumour document mutation PIK3CA gene enrol single-agent dose-expansion phase MTD recommend Phase II dose ( RP2D ) select dose schedule ( appropriate ) explore safety , tolerability , PK , biological activity select dose ( Part B ) . In addition , dose-escalation phase initiate follow observation specific pre-determined criterion single-agent dose escalation , postmenopausal patient oestrogen receptor positive ( ER+ ) , HER2 negative breast cancer receive AZD8835 combination fulvestrant ( Part C ) . The combination dose-escalation phase investigate appropriate combination dose level clinical use . Following combination dose-escalation phase study , additional postmenopausal patient ER+ breast cancer tumour document mutation PIK3CA gene enrol AZD8835 fulvestrant combination dose-expansion phase MTD RP2D ( appropriate ) explore safety , tolerability , PK , biological activity select dose ( Part D ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>1 . Part A : Histological cytological confirmation solid tumor disease progression . Part B : Histological cytological confirmation ER positive , HER2 negative breast cancer disease progression solid tumor PIK3CA gene mutation . Part C : Histological cytological confirmation ER positive , HER2 negative postmenopausal breast cancer locally advance metastatic disease eligible fulvestrant treatment . Part D : Histological cytological confirmation ER positive , HER2 negative postmenopausal breast cancer locally advance metastatic disease eligible fulvestrant treatment . Patients must also present tumor related mutation PIK3CA gene . 2 . Availability archival tumour tissue sample . If archival sample available , fresh tumour biopsy must provide . 3 . At least one measurable lesion per RECIST v1.1 . However , breast cancer patient bone disease also eligible . 4 . ECOG Performance Status 01 . 5 . Adequate organ function baseline : 1 . Serum total bilirubin ≤ 1.5 x ULN AST/SGOT ALT/SGPT ≤ 2.5 x ULN ≤ 5 x ULN liver metastases present . 2 . Creatinine ≤ 1.5 x ULN , calculate measure creatinine clearance ≥ 50 mL/min , 24hour measure urine creatinine clearance ≥ 50 mL/min . 3 . Platelets ≥ 100 x 10^9 , Hb ≥ 90 g/L , ANC ≥ 1.5 x 10^9/L . 4. aPTT ≤ 1.5 x ULN 5 . Fasting glucose &lt; 140 mg/dL ( 7.8 mmol/L ) . 6 . Glycated haemoglobin ( HbA1c ) &lt; 8 % 6 . Female patient male patient female partner child bear potential must use adequate contraception . 1 . Recent chemotherapy , radiotherapy , hormonal therapy , immunotherapy investigational drug within 21 day 5 halfdays enrolment . 2 . Received palliative/focal radiotherapy within 2 week first dose study treatment . 3 . Major surgery ≤ 21 day begin study drug 4 . Any following cardiac criterion : CHF &gt; Class II , cardiac ventricular arrhythmia require therapy , unstable angina newonset angina , QTcF interval &gt; 470ms , abnormal ECHO MUGA baseline ( LVEF &lt; 50 % ) . 5 . Leptomeningeal disease 6 . Part A : Intolerable AEs due PI3K inhibitor , dual PI3K mTOR inhibitor AKT inhibitor . Parts B , C , D : Prior exposure follow : pharmacological inhibitor AKT , PI3K , dual PI3K mTOR kinase activity 7 . Strong inhibitor potent inducer CYP3A4 8 . Peripheral neuropathy CTCAE v4.03 Grade ≥ 3 9 . Diarrhoea CTCAE v4.03 Grade ≥ 2 10 . Acute chronic pancreatitis 11 . Clinically manifest diabetes mellitus , history gestational diabetes mellitus and/or know glucose intolerance . 12 . Patients currently receive medication potential prolong QT interval induce Torsades de Pointes 13 . Spinal cord compression brain metastasis unless asymptomatic require steroid least 4 week 14 . Patients combination arm know hypersensitivity fulvestrant 15 . Therapeutic treatment Coumadin coumarinderivative anticoagulant 16 . Impaired GI function GI disease may interfere absorption AZD8835 patient unable take oral medication 17 . As judged investigator evidence severe uncontrolled systemic disease 18 . Patients treat hematopoietic colonystimulating growth factor e.g. , GCSF , GMCSF , MCSF ) ≤ 2 week prior start . Erythropoietin darbepoetin allow initiate least 2 week prior entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AZD8835</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>PIK3CA Gene Mutation</keyword>
</DOC>